Filing Details

Accession Number:
0001209191-20-027472
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-05-06 16:25:09
Reporting Period:
2020-05-04
Accepted Time:
2020-05-06 16:25:09
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1661567 Michael Parini C/O Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston MA 02210
Evp, Chief Adm, Leg & Bd Off No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-05-04 2,330 $86.52 29,168 No 4 M Direct
Common Stock Disposition 2020-05-04 700 $259.19 28,468 No 4 S Direct
Common Stock Disposition 2020-05-04 700 $260.16 27,768 No 4 S Direct
Common Stock Disposition 2020-05-04 195 $261.21 27,573 No 4 S Direct
Common Stock Disposition 2020-05-04 554 $262.48 27,019 No 4 S Direct
Common Stock Disposition 2020-05-04 181 $264.82 26,838 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-05-04 2,330 $0.00 2,330 $86.52
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
6,990 2027-02-02 No 4 M Direct
Footnotes
  1. Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1.
  2. Open market sales reported on this line occurred at a weighted average price of $259.19 (range $258.74 to $259.63).
  3. Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  4. Open market sales reported on this line occurred at a weighted average price of $260.16 (range $259.74 to $260.64).
  5. Open market sales reported on this line occurred at a weighted average price of $261.21 (range $260.88 to $261.56).
  6. Open market sales reported on this line occurred at a weighted average price of $262.48 (range $261.98 to $262.94).
  7. Open market sales reported on this line occurred at a weighted average price of $264.82 (range $264.77 to $264.89).
  8. The option vests in 16 quarterly installments from 02/03/2017.